RecruitingPhase 3NCT07459296

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Studying Nasopharyngeal carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
First Affiliated Hospital of Guangxi Medical University
Intervention
Becotatug Vedotin(drug)
Enrollment
266 target
Eligibility
18-70 years · All sexes
Timeline
20262032

Study locations (1)

Collaborators

Xiangya Hospital of Central South University · First Affiliated Hospital of Fujian Medical University · Nanfang Hospital, Southern Medical University · Hunan Provincial Cancer Hospital · Affiliated Hospital of North Sichuan Medical College · First Hospital of China Medical University · Guangdong Provincial People's Hospital · First People's Hospital of Yulin · Wuzhou Red Cross Hospital · LiuZhou People's Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07459296 on ClinicalTrials.gov

Other trials for Nasopharyngeal carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Nasopharyngeal carcinoma

← Back to all trials